Total Revenue: Increased 35% year-over-year to $265 million. Royalty Revenue: Increased 39% to $168 million. Adjusted EBITDA: Increased to $162 million, representing approximately 40% year-over-year growth. Net Income: Grew 54% to $118 million. Non-GAAP EPS: Increased to $1.11, representing approximately 40% year-over-year growth. Free Cash Flow: Contributed $153 million in the quarter. Cash, Cash Equivalents, and Marketable Securities: $747.9 million as of March 31, 2025. Net Debt Position: $777 million with a net leverage ratio of 1x. Product Sales: Increased by 33% to $78 million. Collaboration Revenue: Increased by 12% to $18.6 million. Research and Development Expenses: $14.8 million, down from $19.1 million in the prior year period. Selling, General, and Administrative Expenses: $42.4 million, up from $35.1 million in the prior year period. 2025 Revenue Guidance: Raised to $1.2 billion to $1.28 billion, representing growth of 18% to 26%. 2025 Royalty Revenue Guidance: $750 million to $785 million, representing growth of 31% to 37%. 2025 Product Sales Guidance: $340 million to $365 million. 2025 Collaboration Revenue Guidance: $110 million to $130 million. 2025 Adjusted EBITDA Guidance: $790 million to $840 million, representing growth of 25% to 33%. 2025 Non-GAAP EPS Guidance: $5.30 to $5.70, representing growth of 25% to 35%.

Warning! GuruFocus has detected 4 Warning Signs with HALO.

Release Date: May 06, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Total revenue increased by 35% year-over-year to $265 million, driven by strong performance of key products. Royalty revenue grew by 39% to $168 million, primarily due to the success of DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo. Adjusted EBITDA increased by 40% year-over-year to $162 million, indicating strong operational efficiency. Net income rose by 54% to $118 million, showcasing robust profitability. The company announced a $250 million share repurchase plan, reflecting confidence in its financial health and commitment to returning value to shareholders.

Negative Points

The company faces ongoing patent litigation with Merck, which could pose legal and financial risks. Research and development expenses decreased, which might indicate reduced investment in future innovation. Selling, general, and administrative expenses increased, potentially impacting overall profitability. The company is reliant on a few blockbuster products for a significant portion of its revenue, which could pose a risk if market dynamics change. There is uncertainty regarding the outcome of the PGR decisions related to the patent dispute, which could affect future business operations.

Story Continues

Q & A Highlights

Q: Can you comment on the expected timelines for the PGR decisions and what action you could take if the PGR goes in Merck's favor? A: The first decision by the patent office on institution will be in early June. If the case is picked up, it will be reviewed about 12 months from then. If not, it will not proceed. We consider the PGR a side show and are confident in our ability to prevail. Even if Merck wins some PGRs, it won't impact our infringement case, which has multiple additional claims not subject to the PGR.

Q: Was there one particular area of strength that surprised you during the quarter and is driving the upgrade in guidance? A: The strength was broad-based across our three blockbuster products: DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo. We also achieved a milestone on VYVGART Hytrulo one quarter earlier than anticipated. These products continue to perform very well, and we expect strong growth from them for many years.

Q: How do the economics of the small volume auto-injector deal compare to the high-volume auto-injector partnerships? A: Both are development agreements that outline collaboration for clinical development. We haven't moved to commercial licensing yet, but expect a price per device based on manufacturing costs and a cost-plus benefit for Halozyme. We're excited to be working with partners on testing our auto-injectors in clinical studies.

Q: Do you see AstraZeneca's Alteogen deal as evidence that large pharma companies are willing to accept patent litigation risk rather than sign ENHANZE deals? A: No, we haven't heard from any partners pausing due to the Merck litigation. ENHANZE is seen as the market leader, and all companies that signed with Alteogen discussed specific targets with Halozyme first. The trend is that companies come to us first, and we expect this to continue.

Q: How are you thinking about the implications of the ENHERTU frontline breast cancer data for Phesgo sales and royalties? A: We believe Phesgo will continue to demonstrate strong market adoption due to its clinical benefits, convenient administration, and high patient satisfaction. We project continued strong growth for Phesgo, with a 47% share in 58 launch markets, expected to exceed 50% this year.

Q: What are your views on the future mix of royalty revenues as your pipeline evolves? A: We expect several products currently starting their launch trajectories to become meaningful contributors. While DARZALEX will remain important, products like VYVGART Hytrulo and Phesgo will also be significant. Our portfolio is broadening, with multiple high-impact blockbusters expected.

Q: Could you talk about your M&A strategy and expectations for future activity? A: We are focused on drug delivery platforms that can result in long, durable revenues, particularly through royalties. We are not in a hurry and will carefully evaluate opportunities that contribute positively to Halozyme's long-term growth. No specific timeline or size can be commented on at this time.

Q: Can you confirm that the Merck litigation will have no impact on your core ENHANZE business? A: Yes, the MDASE litigation is separate and distinct from ENHANZE and will have no impact on our ENHANZE business or guidance. MDASE represents potential upside from our intellectual property, with no impact on ENHANZE's current or future growth.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments